| Literature DB >> 33096796 |
Clara Martinez-Perez1, Cristina Alvarez-Peregrina1, Cesar Villa-Collar1, Miguel Ángel Sánchez-Tena1.
Abstract
BACKGROUND: The first outbreaks of the new coronavirus disease, named COVID-19, occurred at the end of December 2019. This disease spread quickly around the world, with the United States, Brazil and Mexico being the countries the most severely affected. This study aims to analyze the relationship between different publications and their authors through citation networks, as well as to identify the research areas and determine which publication has been the most cited.Entities:
Keywords: COVID-19; SARS-CoV-2; pandemic; pneumonia; public health
Mesh:
Year: 2020 PMID: 33096796 PMCID: PMC7593954 DOI: 10.3390/ijerph17207690
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Citation networks on COVID-19.
Figure 2Number of publications per month. * Expected date of publication.
Description of the 20 most cited publications on COVID-19.
| Author | Title | Journal | Year | Citation Index | H-Index |
|---|---|---|---|---|---|
| Guan et al. [ | Clinical Characteristics of Coronavirus Disease 2019 in China | New England Journal of Medicine. 2020 Apr; 382(18):1708–1720 | 2020 | 1150 | 1 |
| Zhou et al. [ | Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective | Lancet. 2020 Mar; 395(10229):1054–1062 | 2020 | 793 | 1 |
| Wu et al. [ | Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention | JAMA—Journal of the American Medical Association. 2020 Feb; 322(13):1239–1242 | 2020 | 706 | 1 |
| Hoffmann et al. [ | SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor | Cell. 2020 Apr; 181(2):271–280.e8 | 2020 | 366 | 1 |
| Xu et al. [ | Pathological findings of COVID-19 associated with acute respiratory distress syndrome | Lancet Respiratory Medicine. 2020 Apr;8(4):420–422 | 2020 | 346 | 2 |
| Yang et al. [ | Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study | Lancet Respiratory Medicine. 2020 May;8(5):475–481 | 2020 | 346 | 1 |
| van Doremalen et al. [ | Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 | New England Journal of Medicine. 2020 Apr;382(16):1564–1567 | 2020 | 339 | 2 |
| Mehta et al. [ | COVID-19: consider cytokine storm syndromes and immunosuppression | Lancet. 2020 Mar; 395(10229):1033–1034 | 2020 | 331 | 1 |
| Liang et al. [ | Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China | Lancet Oncology. 2020 Mar;21(3):335–337 | 2020 | 269 | 1 |
| Gao et al. [ | Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies | Bioscience Trends. 2020 Mar; 14(1):72–73 | 2020 | 237 | 1 |
| Cao et al. [ | A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | New England Journal of Medicine. 2020 May; 382(19):1787–1799 | 2020 | 221 | 1 |
| Lai et al. [ | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges | International Journal of Antimicrobial Agents. 2020 Mar;55(3):105924 | 2020 | 203 | 1 |
| Bai et al. [ | Presumed Asymptomatic Carrier Transmission of COVID-19 | JAMA—Journal of the American Medical Association. 2020 Feb 21;323(14):1406–1407 | 2020 | 189 | 1 |
| Shi et al. [ | Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study | Lancet Infectious Diseases. 2020 Apr;20(4):425–434 | 2020 | 186 | 1 |
| Wang et al. [ | Detection of SARS-CoV-2 in Different Types of Clinical Specimens | JAMA—Journal of the American Medical Association. 2020 Mar 11;323(18):1843–1844 | 2020 | 176 | 1 |
| Gorbalenya et al. [ | The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 | Nature Microbiology. 2020 Apr;5(4):536–544 | 2020 | 172 | 1 |
| Fang et al. [ | Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? | Lancet Respiratory Medicine. 2020 Apr;8(4):e21 | 2020 | 153 | 1 |
| Pan et al. [ | Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19) | Radiology. 2020 Jun;295(3):715–721 | 2020 | 152 | 1 |
| Remuzzi et al. [ | COVID-19 and Italy: what next? | Lancet. 2020 Apr;395(10231):1225–1228 | 2020 | 149 | 1 |
| Onder et al. [ | Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy | JAMA—Journal of the American Medical Association. 2020 Mar: 323(18):1775–1776 | 2020 | 144 | 1 |
Figure 3Percentage of publications by research area.
Top 10 journals with the most publications.
| Journal | Total Publications | Impact | Quartile | SJR | Cites/ | Total Cites | H | Country |
|---|---|---|---|---|---|---|---|---|
| BMJ: British Medical Journal | 633 | 30.22 | Q1 | 2.05 | 4.23 | 16,584 | 412 | United Kingdom |
| Cureus | 204 | - | - | - | - | - | - | United States |
| International Journal of Environmental Research and Public Health | 166 | 2.85 | Q1 | 0.74 | 3.18 | 18,252 | 92 | Switzerland |
| Lancet | 166 | 60.39 | Q1 | 14.55 | 44.86 | 60,350 | 747 | United Kingdom |
| Psychological Trauma: Theory Research Practice and Policy | 145 | 2.59 | Q2 | 1.41 | 3.19 | 1052 | 42 | United States |
| Critical Care | 144 | 6.41 | Q1 | 2.38 | 5.59 | 5514 | 160 | United Kingdom |
| Journal of Infection | 138 | 4.84 | Q1 | 1.98 | 4.97 | 1977 | 96 | United Kingdom |
| New England Journal of Medicine | 114 | 74.70 | Q1 | 18.29 | 40.15 | 74,865 | 987 | United States |
| International Journal of Infectious Diseases | 107 | 3.20 | Q1 | 1.44 | 3.33 | 2692 | 79 | The Netherlands |
| JAMA Journal of the American Medical Association | 102 | 45.54 | Q1 | 5.91 | 11.38 | 34,346 | 654 | United States |
Top 10 authors with the largest number of publications.
| Author | Number of Publications | H | Total | Citation |
|---|---|---|---|---|
| Wang Y | 84 | 16 | 1399 | 16.65 |
| Mahase E | 72 | 4 | 88 | 1.22 |
| Li Y | 65 | 8 | 509 | 7.83 |
| Li L | 62 | 9 | 2418 | 39.00 |
| Wang J | 57 | 13 | 1077 | 18.89 |
| Iacobucci G | 56 | 3 | 32 | 0.57 |
| Liu J | 56 | 12 | 2529 | 45.16 |
| Zhang L | 52 | 10 | 849 | 16.33 |
| Zhang Y | 52 | 14 | 2418 | 46.50 |
| Liu Y | 49 | 17 | 4710 | 96.12 |
Figure 4Publication rate by country.
Figure 5The most common keywords.
Figure 6Clustering function in the citation network on COVID-19.
Information on the citation network of the 9 main groups.
| Main Cluster | Number of Publications | Number of Citation Links | Number of Citations Median (Range) | Number of Publications with ≥4 Citations | Number of Publications in the 100 Most Cited |
|---|---|---|---|---|---|
| Group 1 | 4121 | 15,544 | 0 (706–0) | 2214 | 82 |
| Group 2 | 2481 | 6424 | 0 (269–0) | 439 | 5 |
| Group 3 | 960 | 1990 | 0 (57–0) | 459 | 1 |
| Group 4 | 835 | 1220 | 0 (186–0) | 306 | 4 |
| Group 5 | 524 | 1454 | 0 (100–0) | 192 | 5 |
| Group 6 | 519 | 1206 | 0 (89–0) | 275 | 2 |
| Group 7 | 369 | 933 | 1 (55–0) | 137 | 1 |
| Group 8 | 149 | 167 | 0 (16–0) | 141 | 0 |
| Group 9 | 140 | 199 | 0 (22–0) | 139 | 0 |
Figure 7Citation network for Group 1.
Figure 8Citation network for Group 2.
Figure 9Citation network for Group 3.
Figure 10Citation network for Group 4.
Figure 11Citation network for Group 5.
Figure 12Citation network for Group 6.
Figure 13Citation network for Group 7.
Figure 14Citation network for Group 8.
Figure 15Citation network for Group 9.
Figure 16Similarities between the nine main groups.
Figure 17Citation network from the sub-clusters in Group 1.
Main citation network groups from the sub-cluster of Group 1.
| Sub-Cluster | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| No. of publications | 1429 | 1143 | 402 | 234 | 231 |
| No. of citation links | 4875 | 3810 | 863 | 555 | 553 |
| Most cited | Guan et al. [ | Hoffmann et al. [ | Mehta et al. [ | Xiao et al. [ | Tang et al. [ |
| Main Keywords | Covid-19, outbreak, pandemic | Sars-cov-2, virus, Sars | Cytokine storm, inflammation, treatment | Sars coronavirus, pathogenesis, receptor | Coronavirus, transmission, surgery |
| Topic of discussion | Symptoms and signs in COVID-19 patients. | Analyze how the Sars-Cov-2 can pass through human barriers and can infect different types of cells from different species. | Treatment methods | Alterations in the digestive system as a result of COVID-19 | Blood clotting alterations in COVID-19 patients. |
| Conclusion | Clinical findings can help not only to identify the cause of death but also to provide new ideas on the pneumonia’s pathogenesis related to SARS-CoV-2. This may help doctors to give an appropriate response or to provide a therapeutic strategy for critical patients and thus reduce the mortality rate. | SARS-CoV-2 uses SARS-CoV’s ACE2 receptor for the input and the TMPRSS2 serine protease for the priming of protein S. | Treatment using cytokines and/or tocilizumab is likely to become one of the effective approaches for critically ill COVID-19 patients. | It has been shown that digestive symptoms are common in COVID-19 patients. Furthermore, these patients showed longer blood clotting time and increased hepatic enzyme levels. However, more sample studies are needed to confirm these findings. | COVID-19 patients show signs of venous thromboembolism. It has been proven that an anticoagulant therapy, mainly low molecular weight heparin, seems effective. However, more studies are necessary to establish the type of medication, the dose and the optimal duration of the prophylaxis. |
Figure 18Citation network from the sub-clusters of Group 2.
Main citation network groups from the sub-cluster of Group 2.
| Sub-Cluster | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| No. of publications | 509 | 399 | 223 | 176 |
| No. of citation links | 1028 | 830 | 302 | 270 |
| Most cited | van Doremalen et al. [ | Lauer et al. [ | Remuzzi et al. [ | Lai et al. [ |
| Main Keywords | Acute respiratory syndrome, infections, chloroquine | Public health, epidemic, quarantine | Management, personal protective equipment, safety | Epidemiology, sars-cov-2, syndrome |
| Topic of discussion | Evaluate the presence of SARS-CoV-2 on different surfaces. | Evaluate the incubation period of COVID-19 and its effects on public health. | Evaluate the efficiency of the contention methods for reducing COVID-19 outbreaks. | COVID-19 epidemiology |
| Conclusion | The presence of SARS-CoV-2 on different surfaces is very similar to that of SARS-CoV-1. The epidemiological differences between these viruses may be due to the high viral loads in the respiratory tract and the possibility that SARS-CoV-2-infected people could transmit the virus while being asymptomatic. | The mean period of incubation is of 5 days, and in most of the people, the symptoms appear within 11 days. However, these numbers vary between mild cases and severe cases. | Containment methods, such as social distancing or the use of masks, have proven to be effective in limiting virus transmission. Therefore, the general public must be aware of the recommendations regarding COVID-19 contention. | Public health authorities must keep tracking the situation to obtain new information about the virus and its outbreaks in order to estimate the risk of further outbreaks with greater precision. |